Q-omics provides the consensus-scored PTAFR profile across patient tissues and cancer cell-line models. PTAFR expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, PTAFR is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, PTAFR RNA expression shows 22,623 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight SKCM, KIRC, and LSCC as cancer lineages where PTAFR shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PTAFR — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PTAFR survival associations across molecular data types. PTAFR RNA expression shows survival associations in the most cancer types (27), followed by mutation status (4) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PTAFR RNA expression–survival associations across cancer types. High PTAFR expression shows unfavorable associations in LGG, UVM and LAML, but favorable associations in SKCM, DLBC and HNSC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for PTAFR RNA expression.
This table summarizes PTAFR tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PTAFR. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PTAFR shows lower tumor expression in LUSC and LUAD and higher tumor expression in KIRC, STAD, THCA and KIRP. The KIRC box plot shows higher PTAFR RNA expression in tumor versus normal tissue (log2 FC = +1.595, t-test p < 0.001).
This table shows molecular features associated with PTAFR in patient tissues and cancer cell lines. In patient samples, PTAFR shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, PTAFR RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
